Brexpiprazole

Drug Profile

Brexpiprazole

Alternative Names: Lu-AF41156; OPC-34712; OPDC-34712; Rexulti; RXULTI

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Duke University; Lundbeck A/S; Otsuka Pharmaceutical Development & Commercialization
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Piperazines; Quinolines; Small molecules; Thiophenes
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2c adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Norepinephrine plasma membrane transport protein modulators; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder; Schizophrenia
  • Phase III Agitation; Post-traumatic stress disorders; Sleep disorders
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 07 Aug 2017 Otsuka Pharmaceutical Development & Commercialization plans a phase III trial for Schizophrenia (Maintenance treatment, In adolescents) (NCT03238326)
  • 30 Jun 2017 Phase-III clinical trials in Schizophrenia (In adolescents) in USA (PO) (NCT03198078)
  • 20 Jun 2017 Otsuka Pharmaceutical Development & Commercialization, in collaboration with Lundbeck A/S, plans a phase III trial for Schizophrenia (In adolescents, Treatment-experienced) in June 2017 (NCT03198078)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top